

SVRHA LIJEČENJA

Zdravstveni djelatnici (uključujući psihijatre, psihologe, medicinske sestre ili socijalne radnike) surađivat će s oboljelima od shizofrenije i njihovim obiteljima kako bi imali na umu njihove ciljeve. Ciljevi mogu biti kratkoročni ili dugoročni.



Sljedeći dio navodi neke od ciljeva terapije.^{1,2,9}

- Ukloniti ili ublažiti simptome te postići i održati razinu poboljšanja kako ovi simptomi ne bi negativno utjecali na vaš život.
- Spriječiti relaps.
- Spriječiti ili smanjiti dolaske u bolnicu ili potrebu za hospitalizacijom.
- Spriječiti ili ublažiti moguće nuspojave povezane s lijekovima.

Započeti ili se vratiti normalnim svakodnevnim aktivnostima (poput posla, školovanja, samostalnog života i društvenih odnosa).

Literatura

1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004
2. Falkai P et al. *World J Biol Psychiatry* 2005; 6: 132-191.
3. Kendler KS et al. *Arch Gen Psychiatry* 1996; 53: 1022-1031.
4. World Health Organization. *The World Health Report: 2001: Mental health: new understanding, new hope.*
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR).* Arlington: American Psychiatric Publishing Inc. 2000.
6. Lieberman JA et al. *J Clin Psychiatry* 1996; 57(suppl 9): 5-9.
7. Breier A et al. *Am J Psychiatry* 1994; 151: 20-26.
8. Robinson DG et al. *Am J Psychiatry* 1999; 156: 544-549.
9. National Institute for Clinical Excellence. *National Clinical Practice Guidelines Number 82.*
10. Howard R et al. *Am J Psychiatry* 2000; 157: 172-178.
11. Angermeyer MC et al. *Schizophr Bull* 1990; 16: 293-307.
12. Murray RM and Fearon P. *J Psychiatr Res* 1999; 33: 497-499.
13. Lang UE et al. *Cell Physiol Biochem* 2007; 20: 687-702.
14. Harrigan SM et al. *Psychol Med* 2003; 33: 97-110.
15. Bottlender R et al. *Schizophr Res* 2003; 62: 37-44.
16. Lynn Starr h. et al: Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study; *Schizophr Res.* 2018 Apr;194:39-46. doi: 10.1016/j.schres.2017.05.005. Epub 2017 Jun 7
17. Awad AG et al. *Pharmacoeconomics* 2008; 26: 149-162.
18. Keith SJ et al. *Psychiatr Serv* 2004; 55: 997-1005.
19. Lieberman JA et al. *Pharmacol Rev* 2008; 60: 358-403.
20. Tandon R et al. *Psychoneuroendocrinology* 2003; 28(suppl 1): 9-26.
21. Wyatt RJ. *Schizophr Bull* 1991; 17: 325-351

22. Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241-247.
23. Weiden PJ et al. Psychiatr Serv 2004; 55: 886-891.
24. Koen L et al. Psychosomatics 2007; 48: 128-134.
25. Novick D et al. Psychiatry Res 2010; 176: 109-113.
26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27;1603-1611

EM-24040 CRO_MeEd-SCH-WEB-09-10/1/2020